NCT00139360View on ClinicalTrials.gov

Efficacy of Bevacizumab Monotherapy in Treatment of Metastatic Melanoma

PHASE2CompletedINTERVENTIONAL
Enrollment

35

Participants

Timeline

Start Date

May 31, 2005

Primary Completion Date

July 31, 2011

Study Completion Date

July 31, 2011

Conditions
Metastatic Melanoma
Interventions
DRUG

Bevacizumab

Anti angiogenesis treatment

Trial Locations (1)

5020

Department of Oncology, Haukeland University Hospital, Bergen

All Listed Sponsors
collaborator

Norwegian Cancer Society

OTHER

collaborator

Hoffmann-La Roche

INDUSTRY

lead

Haukeland University Hospital

OTHER

NCT00139360 - Efficacy of Bevacizumab Monotherapy in Treatment of Metastatic Melanoma | Biotech Hunter | Biotech Hunter